BioSpace News Archive

SQZ Biotechnologies today announced that the company will host a live R&D investor event with optional virtual participation on Thursday, May 19, 2022, from 4:05 - 5:30 p.m. ET.

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the first quarter ended March 31, 2022 and provided an update on recent operational highlights.

Baudax Bio, Inc., a pharmaceutical company focused on innovative products for acute care settings, announced that it has adjourned its 2022 Annual Meeting of Shareholders, without any business being conducted, due to lack of shareholder participation resulting in a failure to reach required quorum.

Ensysce Biosciences, Inc., a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, announced the release of its 2021 Annual Shareholder Letter authored by Chief Executive Officer, Dr. Lynn Kirkpatrick.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) will present 12-week results from the pivotal Phase 3 SKYLIGHT 1™ clinical trial examining the efficacy and safety of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause (VMS), on Sunday, May 8, 2022 at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting.

Aracari Biosciences, Inc. announces a grant award from the National Institute of Health to further develop Aracari’s proprietary human bone marrow technology that models in vivo drug responses.

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, is pleased to announce the appointment of Alexander A. Zukiwski, MD, to the Company’s Scientific Advisory Board.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2022.

Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2022.

Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, reported financial results for the quarter ended March 31, 2022.